NG-2 (NeuroGenesis)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameNG-2 (NeuroGenesis)
Drug Alias Nameautologous stem cell therapy (NeuroGenesis)NG-2
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionNeuroprotectants
TargetsUpdating
Therapy Area/IndicationsAlzheimer DiseaseMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNeuroGenesis Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNeuroGenesis Bio Inc
Active IndicationsN/A
Inactive IndicationsAlzheimer DiseaseMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A